

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re PATENT Application of)
Tohru Natsume et al.) Confirmation No. 8384
Application No. 10/581,969) Group Art Unit: 1632
Filed: June 7, 2006)
National Stage of)
International Application No. PCT/JP04/18179)
International Filing Date: December 7, 2004)

For: NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT FOR DISUSE
MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH DISUSE MUSCULAR ATROPHY
TAKING ADVANTAGE OF NOVEL INTERACTION

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE; SUBMISSION OF
SEQUENCE LISTING AND
STATEMENT UNDER 37 CFR 1.821**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully submit this Response to the Notification of Defective Response (Notification); Submission of Sequence Listing and Statement Under 37 C.F.R. §1.821, responsive to the Notification mailed April 8, 2008 for the above-captioned Application¹.

Applicants respectfully submit that this Response to the Notification is filed within one (1) month from the mail date of the Notification, and therefore no additional fees are required for entry of this Response. However, in the event of any variance between the amount enclosed and the fees determined by the United States Patent and Trademark Office ("USPTO"), including fees for petition(s) for extension of time, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-2478**.

The Notification indicated that a copy of the sequence listing in computer readable form had been submitted; however, it was stated that the content of the computer readable form did not comply with 37 C.F.R. §§1.822 and/or 1.823. Reviewer Comments enclosed with the Notification explained the deficiencies. Applicants enclose a corrected Sequence Listing, written on paper.

Also, submitted in accordance with 37 CFR 1.821(f) is a computer readable form containing a copy of the Sequence Listing as *txt format file.

¹ Applicants note that a similar Notification had also been mailed on April 3, 2008, which contained no explanation of deficiencies found by the USPTO in the Applicants' sequence listing, filed on February 27, 2008. This Response responds to both Notifications.